|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 11/07/14 Cipher Pharmaceuticals Inc 40FR12B 84:13M Merrill Corp-MD/FA |
Document/Exhibit Description Pages Size
1: 40FR12B Registration of Securities of a Canadian Issuer -- HTML 97K
SEA'34 §12(b)
2: EX-99.01 Miscellaneous Exhibit HTML 31K
3: EX-99.02 Miscellaneous Exhibit HTML 376K
4: EX-99.03 Miscellaneous Exhibit HTML 154K
5: EX-99.04 Miscellaneous Exhibit HTML 44K
6: EX-99.05 Miscellaneous Exhibit HTML 61K
7: EX-99.06 Miscellaneous Exhibit HTML 317K
8: EX-99.07 Miscellaneous Exhibit HTML 32K
9: EX-99.08 Miscellaneous Exhibit HTML 32K
10: EX-99.09 Miscellaneous Exhibit HTML 23K
11: EX-99.10 Miscellaneous Exhibit HTML 557K
12: EX-99.11 Miscellaneous Exhibit HTML 28K
13: EX-99.12 Miscellaneous Exhibit HTML 444K
14: EX-99.13 Miscellaneous Exhibit HTML 27K
15: EX-99.14 Miscellaneous Exhibit HTML 29K
16: EX-99.15 Miscellaneous Exhibit HTML 45K
17: EX-99.16 Miscellaneous Exhibit HTML 27K
18: EX-99.17 Miscellaneous Exhibit HTML 264K
19: EX-99.18 Miscellaneous Exhibit HTML 131K
20: EX-99.19 Miscellaneous Exhibit HTML 28K
21: EX-99.20 Miscellaneous Exhibit HTML 28K
22: EX-99.21 Miscellaneous Exhibit HTML 44K
23: EX-99.22 Miscellaneous Exhibit HTML 41K
24: EX-99.23 Miscellaneous Exhibit HTML 25K
25: EX-99.24 Miscellaneous Exhibit HTML 344K
26: EX-99.25 Miscellaneous Exhibit HTML 169K
27: EX-99.26 Miscellaneous Exhibit HTML 29K
28: EX-99.27 Miscellaneous Exhibit HTML 29K
29: EX-99.28 Miscellaneous Exhibit HTML 40K
30: EX-99.29 Miscellaneous Exhibit HTML 27K
31: EX-99.30 Miscellaneous Exhibit HTML 35K
32: EX-99.31 Miscellaneous Exhibit HTML 351K
33: EX-99.32 Miscellaneous Exhibit HTML 174K
34: EX-99.33 Miscellaneous Exhibit HTML 28K
35: EX-99.34 Miscellaneous Exhibit HTML 28K
36: EX-99.35 Miscellaneous Exhibit HTML 41K
37: EX-99.36 Miscellaneous Exhibit HTML 23K
38: EX-99.37 Miscellaneous Exhibit HTML 23K
39: EX-99.38 Miscellaneous Exhibit HTML 24K
40: EX-99.39 Miscellaneous Exhibit HTML 28K
41: EX-99.40 Miscellaneous Exhibit HTML 406K
42: EX-99.41 Miscellaneous Exhibit HTML 173K
43: EX-99.42 Miscellaneous Exhibit HTML 45K
44: EX-99.43 Miscellaneous Exhibit HTML 40K
45: EX-99.44 Miscellaneous Exhibit HTML 42K
46: EX-99.45 Miscellaneous Exhibit HTML 29K
47: EX-99.46 Miscellaneous Exhibit HTML 28K
48: EX-99.47 Miscellaneous Exhibit HTML 310K
49: EX-99.48 Miscellaneous Exhibit HTML 32K
50: EX-99.49 Miscellaneous Exhibit HTML 32K
51: EX-99.50 Miscellaneous Exhibit HTML 559K
52: EX-99.51 Miscellaneous Exhibit HTML 27K
53: EX-99.52 Miscellaneous Exhibit HTML 424K
54: EX-99.53 Miscellaneous Exhibit HTML 26K
55: EX-99.54 Miscellaneous Exhibit HTML 264K
56: EX-99.55 Miscellaneous Exhibit HTML 156K
57: EX-99.56 Miscellaneous Exhibit HTML 29K
58: EX-99.57 Miscellaneous Exhibit HTML 29K
59: EX-99.58 Miscellaneous Exhibit HTML 44K
60: EX-99.59 Miscellaneous Exhibit HTML 28K
61: EX-99.60 Miscellaneous Exhibit HTML 35K
62: EX-99.61 Miscellaneous Exhibit HTML 32K
63: EX-99.62 Miscellaneous Exhibit HTML 33K
64: EX-99.63 Miscellaneous Exhibit HTML 29K
65: EX-99.64 Miscellaneous Exhibit HTML 33K
66: EX-99.65 Miscellaneous Exhibit HTML 340K
67: EX-99.66 Miscellaneous Exhibit HTML 195K
68: EX-99.67 Miscellaneous Exhibit HTML 29K
69: EX-99.68 Miscellaneous Exhibit HTML 29K
70: EX-99.69 Miscellaneous Exhibit HTML 46K
71: EX-99.70 Miscellaneous Exhibit HTML 354K
72: EX-99.71 Miscellaneous Exhibit HTML 202K
73: EX-99.72 Miscellaneous Exhibit HTML 29K
74: EX-99.73 Miscellaneous Exhibit HTML 29K
75: EX-99.74 Miscellaneous Exhibit HTML 44K
76: EX-99.75 Miscellaneous Exhibit HTML 23K
77: EX-99.76 Miscellaneous Exhibit HTML 369K
78: EX-99.77 Miscellaneous Exhibit HTML 32K
79: EX-99.78 Miscellaneous Exhibit HTML 32K
80: EX-99.79 Miscellaneous Exhibit HTML 23K
81: EX-99.80 Miscellaneous Exhibit HTML 425K
82: EX-99.81 Miscellaneous Exhibit HTML 32K
83: EX-99.82 Miscellaneous Exhibit HTML 32K
84: EX-99.83 Miscellaneous Exhibit HTML 22K
Exhibit 99.46
|
99.46 News Release dated March 25, 2014
INVESTOR RELATIONS CONTACT: |
|
|
Stock Exchange Symbol: DND |
FOR IMMEDIATE RELEASE |
Toronto |
CIPHER APPOINTS THOMAS WELLNER TO BOARD
MISSISSAUGA, Ontario, March 25, 2014 — Cipher Pharmaceuticals Inc. (TSX: DND) (“Cipher” or “the Company”) today announced that Thomas G. Wellner has been appointed to the Board of Directors of the Company.
Most recently, Mr. Wellner was co-CEO of LifeLabs, Canada’s largest laboratory services company, where he was responsible for leading the integration of CML HealthCare into LifeLabs’ organization. Prior to LifeLabs, Mr. Wellner was President and Chief Executive Officer of CML HealthCare, where he led the company through a strategic re-assessment prior to the merger with LifeLabs. Before CML, he spent 20 years with Eli Lilly & Company in a variety of senior operational and strategic leadership roles in Canada, China, United States, Latin America, Europe, and the United Kingdom. Mr. Wellner also served as CEO of Therapure Biopharma from 2008 to 2011.
“We are very pleased to welcome Tom to Cipher’s Board,” said Gerry McDole, Chair of Cipher.
“Tom has a strong background in business development, sales and marketing, and senior management in the healthcare sector. His experience will be a valuable asset to Cipher as the Company expands its product portfolio and operations in the coming years.”
Mr. Wellner currently sits on the Boards of Diamedica (TSX:DMA), Freshbooks (private) and Atlantic Healthcare (private). He is also a Board member of Life Sciences Ontario. Mr. Wellner is a graduate of Queen’s University (B.Sc. Hons. Life Sciences).
As previously disclosed, Larry Andrews, President and CEO, will be leaving Cipher. Accordingly, he will not stand for re-election to the Company’s Board of Directors. Mr. Andrews will remain with the Company for a period of time while the Board undertakes a search process, following which he will continue working with Cipher in a consulting capacity.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: DND) is a growing specialty pharmaceutical company with three commercial products and a fourth in development. Our product candidates are typically improved formulations of successful, currently marketed drugs. We in-license a product, manage the required clinical development and regulatory approval process, and either out-license it to a marketing partner, or, in Canada, we may market the product ourselves. Our core capabilities are in clinical and regulatory affairs, product licensing, supply chain management, and marketing and sales. Since the Company was founded in 2000, we have achieved final regulatory approval in the U.S. and Canada for all three of our original products and completed six marketing partnerships, generating growing licensing revenue.
For more information, please contact:
|
Craig Armitage |
Norm Evans |
|
Investor Relations |
Chief Financial Officer |
|
TMX Equicom |
Cipher Pharmaceuticals |
|
(416) 815-0700 ext 278 |
(905) 602-5840 ext 323 |
|
(416) 815-0080 fax |
(905) 602-0628 fax |
| This ‘40FR12B’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/7/14 | F-X | ||
| 3/25/14 | ||||
| List all Filings | ||||
